Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11977638 | 0.92 | FOLH1 (0.67) | FOLH1 | |
| SCHEMBL17676352 | 0.92 | FOLH1 (0.67) | FOLH1 | |
| SCHEMBL20274494 | 0.90 | FOLH1 (0.55) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL11977611 | 0.88 | FOLH1 (0.70) | FOLH1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL21992144 | 0.87 | FOLH1 (0.69) | FOLH1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11977640 | 0.83 | FOLH1 (0.56) | FOLH1S1PR1ALDH1A1 | |
| SCHEMBL11977626 | 0.82 | FOLH1 (0.80) | FOLH1 | |
| SCHEMBL15449629 | 0.82 | FOLH1 (0.80) | FOLH1 | |
| SCHEMBL11977619 | 0.82 | FOLH1 (0.83) | FOLH1 | |
| SCHEMBL11977607 | 0.81 | FOLH1 (0.84) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309193-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-8487129-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | MOLECULAR INSIGHTS PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208988-A1 | HETERODIMERS OF GLUTAMIC ACID | DDO, GLUL, ASNS | FOLH1 5/4885HDAC3 417/4885HDAC4 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.